iShares US Pharmaceuticals ETF
110 hedge funds and large institutions have $98.2M invested in iShares US Pharmaceuticals ETF in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
9% more funds holding
Funds holding: 101 → 110 (+9)
0.95% more ownership
Funds ownership: 77.5% → 78.45% (+0.95%)
0% less capital invested
Capital invested by funds: $98.4M → $98.2M (-$139K)
12% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
+$1.72M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$939K |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
+$884K |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
+$669K |
| 5 |
Morgan Stanley
New York
|
+$354K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.37M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.21M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$991K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$228K |
| 5 |
AFG
Arkansas Financial Group
Little Rock,
Arkansas
|
-$202K |
IHE Hedge Fund Activity: Q3 2021 in Review
110 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2021, worth a combined $98.2M — down 0.14% from $98.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IHE positions and 5 closed out — a net gain of 9 holders — while 23 added to existing stakes and 26 trimmed.
The largest buyer was Osaic Holdings, adding an estimated $1.72M. The largest seller was Royal Bank of Canada, cutting an estimated $2.37M.
- 110 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2021, up from 101 in Q2 2021.
- Funds reported $98.2M of iShares US Pharmaceuticals ETF stock for Q3 2021, down 0.14% quarter-over-quarter.
- 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2021 and 5 closed out, a net change of +9 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q3 2021 was Osaic Holdings, an estimated $1.72M added.
- The largest iShares US Pharmaceuticals ETF seller in Q3 2021 was Royal Bank of Canada, an estimated $2.37M sold.
Based on aggregated 13F filings for Q3 2021.